BUZZ-Telehealth firms rise as FDA to revisit Lilly's weight-loss drug shortage

Reuters10-14

** Shares of telehealth firms WeightWatchers and Hims & Hers Health rise 3.6% and 5.4%, respectively, in premarket trading

** US FDA on Friday said it will reconsider a decision to bar drug compounders from selling their own versions of Eli Lilly's widely popular weight-loss and diabetes drugs

** In response to a lawsuit brought by an industry group, FDA said it would allow compounding facilities to keep providing the drugs while it reviews whether there is a shortage of tirzepatide

** Tirzepatide is the active ingredient in Lilly's Mounjaro and Zepbound, and was removed from the FDA's shortage list in early October

** Both the telehealth firms, and 23 and Me's unit, LemonAid Health, offer compounded versions of semaglutide, the active ingredient in rival drug Wegovy made by Novo Nordisk

** LLY shares down marginally at $930.86, stock has gained ~60% so far this year

** As of last close, WW was down ~81%, while HIMS shares have more than doubled in value YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment